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Background
Clinical practice guidelines are an increasingly common element of clinical care throughout the world. Such guidelines have the potential to improve the care received by patients by promoting interventions of proven benefit and discouraging ineffective interventions. However, the development and introduction of guidelines are not without costs. In some circumstances, the costs of development and introduction are likely to outweigh their potential benefits. In other circumstances, it may be more efficient to adopt less costly but less effective dissemination and implementation strategies. Local healthcare organisations have relatively few resources for clinical effectiveness activities and policy makers need to consider how best to use these to maximise benefits.
Objectives
The aims of the study were: G to undertake a systematic review of the effectiveness and costs of different guideline development, dissemination and implementation strategies G to estimate the resource implications of different development, dissemination and implementation strategies G to develop a framework for deciding when it is efficient to develop and introduce clinical guidelines based upon the potential costs and benefits of the targeted clinical activity and the effectiveness and costs of guideline development and introduction.
Methods

Systematic review of the effectiveness and efficiency of guideline dissemination and implementation strategies
Data sources MEDLINE (1966 -1998 ), Healthstar (1975 -1998 , Cochrane Controlled Trial Register (4th edition 1998), EMBASE (1980 EMBASE ( -1998 , SIGLE (1980 SIGLE ( -1988 and the specialised register of the Cochrane Effective Practice and Organisation of Care (EPOC) group were searched using a gold standard search strategy developed from handsearches of key journals. The search strategy was 93% sensitive and 18% specific.
Study selection (inclusion criteria)
G Types of study design: randomised controlled trials, controlled clinical trials, controlled before and after studies and interrupted time series G types of participant: medically qualified healthcare professionals G types of intervention: guideline dissemination and implementation strategies G types of outcome: objective measures of provider behaviour and/or patient outcome.
Data extraction (and assessment of validity)
Two reviewers independently abstracted data on the methodological quality of the studies (using the Cochrane EPOC group's methodological quality criteria), characteristics of study setting, participants, targeted behaviours and characteristics of interventions. Studies reporting economic evaluations and cost analyses were further assessed against the British Medical Journal guidelines for reviewers of economic evaluations.
Data synthesis
Single estimates of dichotomous process variables (e.g. proportion of patients receiving appropriate treatment) were derived for each study comparison based upon the primary end-point (as defined by the authors of the study) or the median measure across several reported end-points. An attempt was made to reanalyse studies with common methodological weaknesses. 
Survey of estimating the feasibility and likely resource requirements of guideline dissemination and implementation strategies in UK settings
Telephone interviews were conducted with key informants from primary and secondary care.
Results (research findings)
Systematic review of the effectiveness and efficiency of guideline dissemination and implementation strategies
In total, 235 studies reporting 309 comparisons met the inclusion criteria. The overall quality of the studies was poor. Only 29.4% of comparisons reported any economic data. Eleven reported cost-effectiveness analyses, 38 reported cost consequence analyses (where differences in cost were set against differences in several measures of effectiveness) and 14 reported cost analyses (where some aspect of cost was reported but not related to benefits). The majority of studies only reported costs of treatment; only 25 studies reported data on the costs of guideline development or guideline dissemination and implementation. The majority of studies used process measures for their primary end-point, despite the fact that only three guidelines were explicitly evidence based (and may not have been efficient). Overall, the methods of the economic evaluations and cost analyses were poor. The viewpoint adopted in economic evaluations was only stated in ten studies. The methods to estimate costs were comprehensive in about half of the studies, and few studies reported details of resource use. Owing to the poor quality of reporting of the economic evaluation, data on resource use and cost of guideline development, dissemination and implementation were not available for most of the studies; only four studies provided sufficiently robust data for abstraction.
Survey of estimating the feasibility and likely resource requirements of guideline dissemination and implementation strategies in UK settings
Respondents rarely identified existing budgets to support guideline dissemination and implementation strategies and made frequent comments about using 'soft money' or resources for specific initiatives to support such activities. In general, the respondents thought that only dissemination of educational materials and short (lunchtime) educational meetings were generally feasible within current resources.
Conclusions: implications for healthcare and recommendations for research
There is an imperfect evidence base to support decisions about which guideline dissemination and implementation strategies are likely to be efficient under different circumstances. Decision makers need to use considerable judgement about how best to use the limited resources they have for clinical governance and related activities to maximise population benefits. They need to consider the potential clinical areas for clinical effectiveness activities, the likely benefits and costs required to introduce guidelines and How to obtain copies of this and other HTA Programme reports. An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is also available (see below).
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HTA NHS R&D HTA Programme
T he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.
Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and Emerging Applications of Technology (NEAT); and the Methodology Programme.
